MiddleBrook Pharmaceuticals Announces Promotion Partnership With DoctorDirectory.com For MOXATAG® (extended-release Amoxicillin) Tablets, 775mg

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) announced today that it is partnering with DoctorDirectory.com, Inc. (DoctorDirectory) to promote MOXATAG through DoctorDirectory’s virtual marketing solution, IncreaseRx®. IncreaseRx® utilizes web-based educational and promotional tactics to reach thousands of prescribers with targeted sales and marketing messages. IncreaseRx® performs as a virtual contract sales organization, providing health care professionals with access to electronic sampling and online educational tools and information.

“The IncreaseRx® virtual marketing platform will allow us to expand our reach to thousands of physicians beyond the geography covered by our sales territories,” said John Thievon, president and CEO of MiddleBrook Pharmaceuticals. “We are pleased to partner with DoctorDirectory to promote MOXATAG, the only FDA-approved once-daily amoxicillin.”

Jay Grobowsky, president and CEO of DoctorDirectory, said, “We see MOXATAG as a unique first-line narrow-spectrum antibiotic for the treatment of pharyngitis and tonsillitis and an ideal product for our IncreaseRx® solution. We’re excited to partner with MiddleBrook to expose significant additional prescriber segments to MOXATAG product information and samples to help maximize prescription growth.”

About DoctorDirectory.com, Inc.

DoctorDirectory.com, Inc. is a marketing solutions company that specializes in providing web-based access to health care professionals. IncreaseRx® is a whitespace strategy designed to reach under-performing or inaccessible physician segments and generate incremental revenue. IncreaseRx® utilizes a suite of traditional and web-based tactics to generate incremental revenue for any pharmaceutical brand regardless of product life cycle. For more information about DoctorDirectory’s IncreaseRx® solution please visit www.contactdd.com.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on commercializing anti-infective products that fulfill unmet medical needs. MiddleBrook’s proprietary delivery technology—PULSYS—enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MiddleBrook currently markets MOXATAG – the first and only FDA-approved once-daily amoxicillin – and KEFLEX, the immediate-release brand of cephalexin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., MOXATAG, PULSYS and KEFLEX are our trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademarks applications. Each of the other trademarks, tradenames, or service marks appearing in this document belongs to the respective holder, as used herein, except as otherwise indicated by the context.